OPKO Health (NASDAQ:OPK) Sets New 52-Week High – Still a Buy?

OPKO Health, Inc. (NASDAQ:OPK)’s share price reached a new 52-week high during trading on Friday . The stock traded as high as $1.6051 and last traded at $1.5750, with a volume of 1106308 shares. The stock had previously closed at $1.51.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Barrington Research downgraded OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, OPKO Health currently has a consensus rating of “Hold” and a consensus price target of $1.55.

OPKO Health Stock Up 2.3%

The company has a quick ratio of 3.17, a current ratio of 3.61 and a debt-to-equity ratio of 0.28. The stock has a 50-day simple moving average of $1.29 and a two-hundred day simple moving average of $1.26. The firm has a market cap of $1.17 billion, a PE ratio of -5.73 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $124.20 million during the quarter, compared to analysts’ expectations of $130.51 million. OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The company’s revenue for the quarter was down 17.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.10) EPS. Analysts expect that OPKO Health, Inc. will post -0.29 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Comerica Bank raised its stake in shares of OPKO Health by 7.1% during the fourth quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock worth $151,000 after acquiring an additional 8,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of OPKO Health by 4.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock valued at $262,000 after purchasing an additional 8,954 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of OPKO Health by 11.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 13,912 shares during the last quarter. Intech Investment Management LLC grew its holdings in shares of OPKO Health by 11.4% during the 4th quarter. Intech Investment Management LLC now owns 159,652 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 16,329 shares during the last quarter. Finally, Swiss Life Asset Management Ltd purchased a new position in OPKO Health in the 3rd quarter worth $30,000. 64.63% of the stock is currently owned by institutional investors.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.